As immunotherapies and even newer strategies such as antisense therapy march ahead, the drug development pipeline took an interesting turn this year. Here, we look back at the compounds that made the cut, as well as those that got cut.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Drugs that made headlines in 2013. Nat Med 19, 1562–1563 (2013). https://doi.org/10.1038/nm1213-1562
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm1213-1562
